Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.30 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5474064 | 1.00 | PTPN1 (0.37) | PTPN1PTGS2SIRT2TRPV1PTGS1 | |
| SCHEMBL5471648 | 1.00 | PTPN1 (0.37) | PTPN1PTGS2SIRT2TRPV1PTGS1 | |
| SCHEMBL5470101 | 1.00 | PTPN1 (0.37) | PTPN1PTGS2SIRT2TRPV1PTGS1 | |
| SCHEMBL5474046 | 1.00 | PTPN1 (0.37) | PTPN1PTGS2SIRT2TRPV1PTGS1 | |
| Bo-653 SCHEMBL5055886 | 0.99 | PTPN1 (0.36) | PTPN1PTGS2SIRT2TRPV1PTGS1 | |
| SCHEMBL5467048 | 0.95 | PTGS2 (0.32) | PTPN1PTGS2TRPV1PTGS1ALOX5 | |
| SCHEMBL5477593 | 0.90 | CA2 (0.32) | — | |
| SCHEMBL5466692 | 0.84 | HSPA5 (0.36) | — | |
| SCHEMBL5472303 | 0.82 | CA2 (0.33) | — | |
| SCHEMBL5477925 | 0.81 | ALOX5 (0.32) | PTGS2PTGS1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066681-A1 | Pharmaceutical composition for treating fatty liver or hepatic disease | CHUGAI SEIYAKU KAUSHIKI KAISHA (JP) | 2007-03-22 | — | — | US | disclosed |
| EP-1666035-A1 | MEDICINAL COMPOSITION FOR TREATMENT FOR FATTY LIVER OR LIVER DISEASE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-06-07 | — | — | EP | disclosed |
| US-20050159481-A1 | Medicinal composition for improving angiotension-regulating function of blood vessel endothelium | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-07-21 | — | — | US | disclosed |
| EP-1496054-A1 | MEDICINAL COMPOSITION FOR IMPROVING ANGIOTENSION-REGULATING FUNCTION OF BLOOD VESSEL ENDOTHELIUM | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-20040242678-A1 | Apolipo protein e secretion promoters | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1428529-A1 | APOLIPO PROTEIN E SECRETION PROMOTERS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159481-A1 | Medicinal composition for improving angiotension-regulating function of blood vessel endothelium | EDNRA, EDNRB, LIPG | PTPN1 1694/4885PTGS2 190/4885SIRT2 971/4885 |
| US-20040242678-A1 | Apolipo protein e secretion promoters | APOB, APOL1, SREBF1 | PTPN1 3515/4885PTGS2 1372/4885SIRT2 3699/4885 |
| US-20070066681-A1 | Pharmaceutical composition for treating fatty liver or hepatic disease | LIPC, CPT1A, FABP1 | PTPN1 2790/4885PTGS2 792/4885SIRT2 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.